Hi Tony,
Yes, I realise that Nick was talking about a different bug to Pseudomonas aeruginosa which is the focus of the Medlmmune collaboration. I thought it was significant, however, that Nick should highlight the antibiotic potency of peptide candidates.
We have already been advised that new deals are being negotiated with existing partners. Its quite possible that the antibiotic discovery collaboration with Medlmmune could be expanded.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
0.005(0.37%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.40 | $1.36 | $211.9K | 152.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4103 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 2028 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |